700-Patient study aims to unlock secrets of CAR-T cancer treatment
NCT ID NCT07609485
First seen Jun 08, 2026 · Last updated Jun 12, 2026 · Updated 2 times
Summary
This study collects blood and tumor samples from 700 adults with blood cancers who are receiving CAR-T therapy. Researchers want to understand why about 40% of patients respond well while others relapse or don't respond at all. By studying the cells and molecules involved, they hope to find ways to make CAR-T therapy more effective for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hop Claude Huriez Chu Lille
TERMINATEDLille, 59037, France
-
chu de Lille
RECRUITINGLille, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.